| |
Men
|
Women
|
---|
| |
Abstainers
|
0.1-19.9 g/d
|
20.0-39.9 g/d
|
≥40.0 g/d
|
Abstainers
|
≥0.1 g/d
|
---|
Diabetes
|
cases/non-cases, n
|
95/593
|
74/312
|
13/129
|
32/187
|
206/1429
|
12/165
|
|
Model 1
|
1.0 (reference)
|
1.53 (1.09,2.14)
|
0.65 (0.35,1.20)
|
1.11 (0.72,1.71)
|
1.0 (reference)
|
0.51 (0.28,0.94)
|
|
Model 2
|
1.0 (reference)
|
1.25 (0.87,1.79)
|
0.72 (0.38,1.37)
|
1.57 (0.97,2.54)
|
1.0 (reference)
|
0.39 (0.21,0.73)
|
|
Model 3
|
1.0 (reference)
|
1.26 (0.88,1.81)
|
0.74 (0.39,1.40)
|
1.61 (0.99,2.60)
|
1.0 (reference)
|
0.39 (0.21,0.73)
|
|
Model 4
|
1.0 (reference)
|
1.30 (0.90,1.89)
|
0.69(0.36,1.32)
|
1.56 (0.96,2.53)
|
1.0 (reference)
|
0.42 (0.22,0.78)
|
|
Model 5
|
1.0 (reference)
|
1.27 (0.87,1.86)
|
0.70 (0.37,1.35)
|
1.59 (0.96,2.61)
|
1.0 (reference)
|
0.41 (0.22,0.78)
|
Combined diabetes and IFG
|
cases/non-cases, n
|
270/418
|
211/175
|
52/90
|
107/112
|
596/1039
|
75/102
|
|
Model 1
|
1.0 (reference)
|
1.86 (1.44,2.39)
|
0.89 (0.61,1.29)
|
1.47 (1.08,2.00)
|
1.0 (reference)
|
1.31 (0.96,1.80)
|
|
Model 2
|
1.0 (reference)
|
1.40 (1.07,1.85)
|
0.81 (0.54,1.20)
|
1.58 (1.12,2.22)
|
1.0 (reference)
|
0.97 (0.69,1.36)
|
|
Model 3
|
1.0 (reference)
|
1.42 (1.07,1.87)
|
0.82 (0.55,1.23)
|
1.64 (1.16,2.33)
|
1.0 (reference)
|
0.98 (0.70,1.38)
|
|
Model 4
|
1.0 (reference)
|
1.38 (1.03,1.84)
|
0.77 (0.51,1.16)
|
1.47 (1.03,2.10)
|
1.0 (reference)
|
1.03 (0.72,1.47)
|
|
Model 5
|
1.0 (reference)
|
1.36 (1.02,1.82)
|
0.80 (0.53,1.22)
|
1.50 (1.04,2.15)
|
1.0 (reference)
|
1.03 (0.72,1.47)
|
- Model 1: Adjusted for age
- Model 2: Adjusted for age, geographic location (north/south), residential region (urban/rural), educational level, smoking, physical activity, family income, family history of CVD or diabetes, and diet (total energy intake without alcohol, energy adjusted dietary fiber and fat intake).
- Model 3: Adjusted variables in model 2 plus BMI
- Model 4: Adjusted variables in model 3 plus inflammatory markers (log-transformed CRP, IL-6 and ferritin)
- Model 5: Adjusted variables in model 4 plus adipokines (RBP4, log-transformed adiponectin and PAI-1)